Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab

Author:

Kobayashi Takashi1ORCID,Ito Katsuhiro2ORCID,Kojima Takahiro3,Kato Minoru4,Kanda Souhei5,Hatakeyama Shingo6,Matsui Yoshiyuki7,Matsushita Yuto8,Naito Sei9,Shiga Masanobu3,Miyake Makito10ORCID,Muro Yusuke11,Nakanishi Shotaro12,Kato Yoichiro13,Shibuya Tadamasa14,Hayashi Tetsutaro15,Yasumoto Hiroaki16,Yoshida Takashi17,Uemura Motohide18,Taoka Rikiya19,Kamiyama Manabu20,Ogawa Osamu1,Kitamura Hiroshi21,Nishiyama Hiroyuki3,

Affiliation:

1. Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan

2. Department of Urology Ijinkai Takeda General Hospital Kyoto Japan

3. Department of Urology University of Tsukuba Tsukuba Japan

4. Department of Urology Osaka City University Osaka Japan

5. Department of Urology Akita University Akita Japan

6. Department of Urology Hirosaki University Hirosaki Japan

7. Department of Urology National Cancer Center Hospital Tokyo Japan

8. Department of Urology Hamamatsu University School of Medicine Hamamatsu Japan

9. Department of Urology Faculty of Medicine Yamagata University Yamagata Japan

10. Department of Urology Nara Medical University Kashihara Japan

11. Department of Urology Shizuoka General Hospital Shizuoka Japan

12. Department of Urology University of the Ryukyus Nishihara Japan

13. Department of Urology Iwate Medical University Morioka Japan

14. Department of Urology Oita University Yufu Japan

15. Department of Urology Hiroshima University Hiroshima Japan

16. Department of Urology Shimane University Izumo Japan

17. Department of Urology Kansai Medical University Hirakata Japan

18. Department of Urology Osaka University Suita Japan

19. Department of Urology Kagawa University Kita Japan

20. Department of Urology University of Yamanashi Chuo Japan

21. Department of Urology Toyama University Toyama Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3